Corbus Pharmaceuticals (CRBP) closed the most recent trading day at $7.64, moving -0.52% from the previous trading session. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.21%, and the Nasdaq, a tech-heavy index, added 0.13%.
Coming into today, shares of the drug developer had lost 1.29% in the past month. In that same time, the Medical sector gained 3.05%, while the S&P 500 gained 5.36%.
Wall Street will be looking for positivity from CRBP as it approaches its next earnings report date. On that day, CRBP is projected to report earnings of -$0.22 per share, which would represent a year-over-year decline of 10%.
Investors should also note any recent changes to analyst estimates for CRBP. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 8.57% higher. CRBP is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 74, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report
Original post